$JAGX BOUNCE PLAY ---> Jaguar Health, Inc. - 💵💵💯

Jaguar Health, Inc. is a natural-products pharmaceuticals company. It focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals. The company through its subsidiary Napo Pharmaceuticals Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals. Its product pipeline consists of Mytesi(R), Canalevia(TM), Equilevia(TM) and Neonorm (TM). Jaguar Health Inc., formerly known as Jaguar Animal Health Inc., is based in San Francisco, United States.

Recent News:

Jaguar Health Subsidiary Napo Pharmaceuticals Issues Further Regulatory Update Regarding Potential Follow-on Indication for MytesiACCESSWIRE - Tue Apr 2, 5:01AM CDT
Jaguar Health Issues Regulatory Update Regarding Potential Follow-on Indication for MytesiACCESSWIRE - Thu Mar 28, 5:01AM CDT
Jaguar Completes Filing of CMC Technical Section with FDA for Use of Canalevia for Treatment of Chemotherapy-Induced Diarrhea in DogsACCESSWIRE - Wed Mar 20, 5:31AM CDT
Human Health Products:

Mytesi® (crofelemer), a product of Jaguar’s wholly-owned subsidiary Napo Pharmaceuticals, is approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. More information and complete Prescribing Information are available at Mytesi.com.

Jaguar controls global unencumbered rights to key indications for Mytesi®, and is pursuing a follow-on indication for Mytesi® in cancer therapy-related diarrhea (CTD), an important supportive care indication for patients undergoing primary or adjuvant chemotherapy for cancer treatment. Mytesi® is also in development for rare disease indications for infants and children with congenital diarrheal disorders and short bowel syndrome (SBS); for irritable bowel syndrome (IBS) (Mytesi® has demonstrated a reduction in pain in IBS-D patients in Phase 2 studies); for supportive care for inflammatory bowel disease (IBD); and as a second-generation anti-secretory agent for use in cholera patients. Mytesi® has received orphan-drug designation for SBS.

Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.